In this webinar we discuss the when and why to use ultrasound enhancing agents (UEAs). This includes when two or more LV segments cannot be visualized adequately for the assessment of LV function (LVEF and RWM assessment) and/or in settings in which the study indication requires accurate analysis of RWMA (JASE 2018). Current information on safety and optimization is discussed and we explore Cardio-Oncology and how best to monitor cardiotoxicity. Lastly, we cover current updates of UEA roles in the evaluation of masses including perfusion techniques.
- When, why, and how should I use ultrasound enhancing
- Current recommendations
- What is it? Why is it important?
- What imaging should I use to monitor for cardiotoxicity?
- 2D, 3D, ultrasound enhancing agents
- Usefulness of Strain
- UEA for mass perfusion
- Thrombus vs Tumor?
- Optimizing perfusion techniques
This program has been designed for physicians with an interest in cardiac imaging (including, but not limited to, cardiologists, interventional cardiologists, cardiac, and vascular surgeons)
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. Northwest Imaging Forums is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical ducation for physicians. NWIF designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release Date: 7/8/2020 | Expires: 7/8/2021
Rupal O’Quinn, MD, FACC
- Bracco – honoraria for unrestricted educational conference (ROQ and MM) and consulting in 2018 (ROQ)
- Discussion of off-label use of ultrasound enhancing agents
Michelle McGovern, RDCS
- No Disclosures